ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Dr. Reddy's Laboratories Ltd.

Business Summary

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Financial Highlights

Mar 2022 INRUSD
Gross Profit107,643M1,444.68M
Operating income34,483M462.79M
Income before tax31,595M424.03M
Net income23,568M316.30M
Diluted EPS141.681.90
Dividends Per Share300.40
Total Assets292,827M3,864.42M
Total liabilities102,300M1,350.04M
Total equity190,527M2,514.37M
Operating cash flow27,636M370.90M
Currency in INRCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 142,028M 153,851M 174,600M 189,722M 214,391M
Gross Profit 71,189M 78,008M 88,078M 96,342M 107,643M
Operating income 11,182M 19,584M 28,637M 32,028M 34,483M
Income before tax 13,997M 22,005M 17,471M 25,933M 31,595M
Net income 9,806M 18,795M 19,498M 17,238M 23,568M
EBITDA 22,892M 31,774M 41,109M 44,824M 46,307M
Diluted EPS 59.01 113.09 117.39 103.64 141.68
Dividends Per Share 20 20 25 25 30
Total Assets 225,604M 225,427M 232,241M 265,491M 292,827M
Total liabilities 99,144M 85,230M 77,253M 92,429M 102,300M
Total equity 126,460M 140,197M 154,988M 173,062M 190,527M
Operating cash flow 17,110M 27,878M 29,249M 35,602M 27,636M
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 2,203.14M 2,199.67M 2,462.41M 2,555.69M 2,877.35M
Gross Profit 1,104.28M 1,115.31M 1,242.17M 1,297.79M 1,444.68M
Operating income 173.45M 280.00M 403.87M 431.44M 462.79M
Income before tax 217.12M 314.61M 246.39M 349.33M 424.03M
Net income 152.11M 268.71M 274.98M 232.20M 316.30M
EBITDA 355.10M 454.28M 579.76M 603.81M 621.49M
Diluted EPS 0.91 1.61 1.65 1.39 1.90
Dividends Per Share 0.31 0.28 0.35 0.33 0.40
Total Assets 3,459.03M 3,254.08M 3,069.88M 3,631.20M 3,864.42M
Total liabilities 1,520.10M 1,230.31M 1,021.17M 1,264.18M 1,350.04M
Total equity 1,938.92M 2,023.77M 2,048.71M 2,367.02M 2,514.37M
Operating cash flow 265.41M 398.58M 412.50M 479.58M 370.90M

Valuation Measures

Mar 2022
Operating margin16.08%
Profit margin10.99%

Key executives

  • Chief Executive Officer: Erez Israeli
  • Chief Financial Officer: Parag Agarwal
  • Chief Digital & Information Officer: Mukesh Rathi
  • Secretary & Compliance Officer: K. Randhir Singh
  • CEO-India & Emerging Markets Branded Markets: M. V. Ramana


  • APS Trust (20.6%)
  • Life Insurance Corporation of India (Investment Portfolio) (5.6%)
  • First Sentier Investors (Australia) IM Ltd. (3.5%)
  • Exide Life Insurance Co. Ltd (2.9%)
  • SBI Funds Management Pvt Ltd. (2.6%)
  • Aditya Birla Sun Life Amc Ltd. (Investment Management) (2.0%)
  • BlackRock Fund Advisors (1.8%)
  • The Vanguard Group, Inc. (1.7%)
  • GIC Pte Ltd. (Investment Management) (1.7%)

Contact Details

  • Website:
  • Address: Door No. 8-2-337, Road No. 3, Hyderabad, 500034, India
  • Phone: +91.40.49002900

Related Companies

  • Dr. Reddys Laboratories Ltd. /4 Brands/
  • Dr. Reddy's Laboratories Ltd. /2 Brands/
  • Nimbus Health GmbH
  • Dr. Reddy's Farmaceutica do Brasil Ltda.
  • Dr. Reddy's Employees ESOS Trust
  • Dr. Reddy's Research Foundation
  • BMS Laboratories Ltd.
  • Wockhardt Ltd. /Domestic Formulations Bus/
  • Imperial Credit Pvt Ltd.
  • Ducere Pharma LLC/Otc Bus/
  • UCB SA /Established Product Bus/
  • Dr. Reddy's Laboratories SA
  • Zenovus Biotech Pvt Ltd.
  • Regkinetics Services Ltd.
  • Dr. Reddy's Bio-Sciences Ltd.
  • Idea2Enterprises (India) Pvt Ltd.
  • Industrias Quimicas Falcon de Mexico SA de CV
  • Kunshan Rotam Reddy Pharmaceutical Co., Ltd.
  • Aurigene Discovery Technologies Ltd.
  • Perlecan Pharma Pvt Ltd.
  • Macred India Pvt Ltd.
  • BASF SE /Pharmaceutical Contract Manufacturing Unit/
  • Dowpharma /Small Molecules Business/
  • Laboratorios Litaphar SA
  • F. Hoffmann-La Roche Ltd. /Drug Ingredient Making Plant/
  • Trigenesis Therapeutics, Inc.


  • Amneal Pharmaceuticals, Inc. Class A
  • Perrigo Co. Plc
  • KRKA dd
  • Teva Pharmaceutical Industries Limited
  • Hikma Pharmaceuticals Plc
  • Novartis AG
  • Pfizer Limited
  • Sanofi
  • Aurobindo Pharma Ltd
  • Cipla Ltd
  • Lupin Limited
  • Glenmark Pharmaceuticals Limited
  • Fresenius SE & Co. KGaA
  • Alkem Laboratories Ltd.
  • Zydus Lifesciences Limited
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Viatris, Inc.
  • Sanofi India Limited
  • Piramal Enterprises Ltd.
  • Sun Pharmaceutical Industries Limited
  • GlaxoSmithKline Pharmaceuticals Limited
  • Endo International Plc
  • Abbott India Limited
  • STADA Arzneimittel AG
  • Syngene International Ltd.
  • Granules India Limited
  • WuXi AppTec Co., Ltd. Class H
  • Lonza Group AG
  • Zhejiang Huahai Pharmaceutical Co., Ltd. Class A
  • Dishman Carbogen Amcis Ltd.
Last Updated on 5 Aug, 2022

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more